Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine

Clin Immunol. 2022 Apr:237:108963. doi: 10.1016/j.clim.2022.108963. Epub 2022 Mar 5.

Abstract

Convalescent coronavirus disease 2019 (COVID-19) subjects who receive BNT162b2 develop robust antibody responses against SARS-CoV-2. However, our understanding of the clonal B cell response pre- and post-vaccination in such individuals is limited. Here we characterized B cell phenotypes and the BCR repertoire after BNT162b2 immunization in two convalescent COVID-19 subjects. BNT162b2 stimulated many B cell clones that were under-represented during SARS-CoV-2 infection. In addition, the vaccine generated B cell clusters with >65% similarity in CDR3 VH and VL region consensus sequences both within and between subjects. This result suggests that the CDR3 region plays a dominant role adjacent to heavy and light chain V/J pairing in the recognition of the SARS-CoV-2 spike protein. Antigen-specific B cell populations with homology to published SARS-CoV-2 antibody sequences from the CoV-AbDab database were observed in both subjects. These results point towards the development of convergent antibody responses against the virus in different individuals.

Keywords: Antibodies; B cells; COVID19; SARS CoV2.

MeSH terms

  • Antibodies, Viral* / immunology
  • Antibody Formation
  • BNT162 Vaccine* / immunology
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Complementarity Determining Regions* / genetics
  • Humans
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus / immunology

Substances

  • Antibodies, Viral
  • Complementarity Determining Regions
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2
  • BNT162 Vaccine